Another SKP2 antagonist of this type is DT204, which overcomes Bortezomib resistance in multiple myeloma by reducing the interaction of SKP2 with Cullin1 and Commd1 adaptor thereby disrupting SCFSKP2 complex.271. This evidence concerns the gene SKP2 and plasma cell myeloma.